Recent studies indicate that HDAC inhibitors can provide a therapeutic effect in various cancers, such as B-cell lymphoma, leukemia, multiple myeloma and some virus-associated cancers. This evidence concerns the gene HDAC9 and B-cell non-Hodgkin lymphoma.